Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from relapsing multiple sclerosis.

The aim of the study was to examine the effect of cladribine used in the treatment of relapsing multiple sclerosis on an oral contraceptive containing ethinyl estradiol and levonorgestrel.

Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase.

Go back

News

Completion of a single-center phase I study of the safety and pharmacokinetics of CPL207280

We have just completed a phase I study of safety and pharmacokinetics (part B) of an innovative therapy that could be used...

Read more …

GcLP quality certificate for laboratory procedures

The BRG Clinical Site received the GcLP quality certificate for laboratory procedures and is in the process of obtaining GMP certification for pharmaceutical procedures.

Read more …

Study for healthy people with a drug against Covid-19

In BRG we are currently performing a study for healthy people with a drug against Covid-19 .
In the project we are comparing experimental injectable drug called...

Read more …

Phase I study finished

Our site has just succesfully finished clinical stage of phase I (two parts) study with JAK kinase inhibitors.

Read more …

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

In BRG we are just starting Study for Healthy People with an Immune Drug - Part B. The aim of the following clinical trial...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲